Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (323) 323
Publication (27) 27
Newsletter (12) 12
Book Review (6) 6
Magazine Article (3) 3
Newspaper Article (3) 3
Book Chapter (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
eltrombopag (337) 337
humans (228) 228
index medicus (224) 224
thrombocytopenia (158) 158
hematology (148) 148
romiplostim (130) 130
female (116) 116
hydrazines - therapeutic use (115) 115
benzoates - therapeutic use (114) 114
pyrazoles - therapeutic use (114) 114
receptors, thrombopoietin - agonists (112) 112
male (109) 109
purpura, thrombocytopenic, idiopathic - drug therapy (106) 106
thrombopoietin (101) 101
adult (90) 90
middle aged (86) 86
double-blind (83) 83
immune thrombocytopenia (83) 83
efficacy (81) 81
purpura (81) 81
platelet count (77) 77
thrombopoietin - therapeutic use (69) 69
treatment outcome (69) 69
receptors, fc - therapeutic use (68) 68
management (67) 67
safety (60) 60
thrombocytopenia - drug therapy (60) 60
pharmacology & pharmacy (59) 59
recombinant fusion proteins - therapeutic use (59) 59
aged (58) 58
care and treatment (56) 56
benzoates - adverse effects (52) 52
hydrazines - adverse effects (52) 52
pyrazoles - adverse effects (52) 52
adults (51) 51
platelets (49) 49
itp (48) 48
oncology (48) 48
splenectomy (47) 47
benzoates - administration & dosage (44) 44
hydrazines - administration & dosage (44) 44
pyrazoles - administration & dosage (44) 44
patients (42) 42
idiopathic thrombocytopenic purpura (38) 38
drug therapy (37) 37
immune thrombocytopenic purpura (37) 37
medicine & public health (37) 37
thrombopoietin receptor agonist (37) 37
young adult (37) 37
health aspects (36) 36
analysis (34) 34
chronic disease (34) 34
rituximab (34) 34
adolescent (33) 33
blood platelets (32) 32
controlled-trial (31) 31
clinical trials (29) 29
dosage and administration (29) 29
internal medicine (28) 28
thrombopoietin - adverse effects (28) 28
benzoates - pharmacology (27) 27
hydrazines - pharmacology (27) 27
long-term (27) 27
medicine, general & internal (27) 27
pharmacokinetics (27) 27
purpura, thrombocytopenic, idiopathic - blood (27) 27
pyrazoles - pharmacology (27) 27
aged, 80 and over (26) 26
animals (26) 26
children (26) 26
cirrhosis (26) 26
research (26) 26
hemic and lymphatic diseases (25) 25
therapy (25) 25
recombinant fusion proteins - adverse effects (24) 24
retrospective studies (22) 22
thrombocytopenic purpura (22) 22
amg-531 (21) 21
anemia (21) 21
aplastic anemia (21) 21
blood platelets - drug effects (21) 21
bone marrow (21) 21
review (21) 21
thrombopoietin receptor agonists (21) 21
thrombosis (21) 21
chemotherapy (20) 20
chronic itp (20) 20
risk factors (20) 20
benzoates - pharmacokinetics (19) 19
bleeding (19) 19
hydrazines - pharmacokinetics (19) 19
pyrazoles - pharmacokinetics (19) 19
receptors, fc - administration & dosage (19) 19
thrombopoietin-receptor agonists (19) 19
transplantation (19) 19
abridged index medicus (18) 18
child (18) 18
dose-response relationship, drug (18) 18
hematology, oncology and palliative medicine (18) 18
hematopoiesis (18) 18
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia
by Townsley, Danielle M and Scheinberg, Phillip and Winkler, Thomas and Desmond, Ronan and Dumitriu, Bogdan and Rios, Olga and Weinstein, Barbara and Valdez, Janet and Lotter, Jennifer and Feng, Xingmin and Desierto, Marie and Leuva, Harshraj and Bevans, Margaret and Wu, Colin and Larochelle, Andre and Calvo, Katherine R and Dunbar, Cynthia E and Young, Neal S
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1540 - 1550
In a phase 2 clinical trial, eltrombopag plus standard immunosuppression resulted in a 6-month complete-response rate of 58% among patients receiving... 
CELLS | MEDICINE, GENERAL & INTERNAL | THERAPY | MARROW | HEMATOPOIESIS | HORSE | ANTITHYMOCYTE GLOBULIN | THROMBOCYTOPENIA | MUTATIONS | MYELODYSPLASTIC SYNDROMES | CYCLOSPORINE | Antigens, CD34 | Benzoates - adverse effects | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Prospective Studies | Cell Count | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Young Adult | Antilymphocyte Serum - therapeutic use | Adult | Female | Drug Therapy, Combination | Pyrazoles - adverse effects | Hematologic Agents - adverse effects | Hydrazines - therapeutic use | Hematologic Agents - therapeutic use | Cyclosporine - therapeutic use | Receptors, Thrombopoietin - agonists | Immunosuppression | Adolescent | Anemia, Aplastic - drug therapy | Aged | Hydrazines - adverse effects | Treatment outcome | Eltrombopag | Analysis | Patient outcomes | Aplastic anemia | Dosage and administration | Drug therapy | Immunosuppressive agents | CD34 antigen | Anemia | Cell number | Research & development--R&D | Bone marrow | Age | Thrombopoietin | Hemopoiesis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text The temporary use of thrombopoietin‐receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study
by Mahévas, Matthieu and Fain, Olivier and Ebbo, Mikael and Roudot‐Thoraval, Françoise and Limal, Nicolas and Khellaf, Mehdi and Schleinitz, Nicolas and Bierling, Philippe and Languille, Laeticia and Godeau, Bertrand and Michel, Marc
British Journal of Haematology, ISSN 0007-1048, 06/2014, Volume 165, Issue 6, pp. 865 - 869
Summary Thrombopoietin‐receptor agonists (Tpo‐RAs) are highly effective in immune thrombocytopenia (ITP). Recently, cases of durable remission after Tpo‐RA... 
durable response | prolonged remission | thrombopoietin‐receptor agonists | immune thrombocytopenia | Immune thrombocytopenia | Durable response | Prolonged remission | Thrombopoietin-receptor agonists | LONG-TERM | EFFICACY | ITP | SAFETY | ROMIPLOSTIM | PURPURA | thrombopoietin-receptor agonists | CIRRHOSIS | BIOLOGY | ELTROMBOPAG | AGENTS | HEMATOLOGY | Purpura, Thrombocytopenic, Idiopathic - surgery | Hydrazines - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Thrombopoietin - therapeutic use | Treatment Outcome | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Receptors, Fc - therapeutic use | Splenectomy | Young Adult | Receptors, Thrombopoietin - agonists | Aged, 80 and over | Adult | Female | Aged | Drug Therapy, Combination | France | Immunologic Factors - therapeutic use | Thrombocytopenia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia
by Gill, Harinder and Leung, Garret M. K and Lopes, David and Kwong, Yok‐Lam
British Journal of Haematology, ISSN 0007-1048, 03/2017, Volume 176, Issue 6, pp. 991 - 994
treatment | romiplostim | eltrombopag | aplastic anaemia | HEMATOPOIESIS | HEMATOLOGY | Hydrazines - pharmacology | Hydrazines - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Recombinant Fusion Proteins - pharmacology | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Thrombopoietin - therapeutic use | Thrombopoietin - pharmacology | Receptors, Fc - therapeutic use | Young Adult | Anemia, Aplastic - drug therapy | Benzoates - pharmacology | Adult | Female | Aged | Pyrazoles - pharmacology | Care and treatment | Aplastic anemia | Anemia | Thrombopoietin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia
by Kuter, David J
Annual Review of Medicine, ISSN 0066-4219, 2009, Volume 60, Issue 1, pp. 193 - 206
Although the thrombopoietin receptor was discovered in 1991 and thrombopoietin (TPO) was purified in 1994, the development of a clinically useful TPO was... 
Romiplostim | Eltrombopag | Platelets | Immune thrombocytopenic purpura (ITP) | FACTOR PEG-RHUMGDF | ANTIBODIES | RECOMBINANT HUMAN THROMBOPOIETIN | PLATELET PRODUCTION | eltrombopag | platelets | MEDICINE, GENERAL & INTERNAL | CYTOKINE RECEPTOR | HUMAN MEGAKARYOCYTE GROWTH | DOUBLE-BLIND | romiplostim | C-MPL | immune thrombocytopenic purpura (ITP) | AGONIST | Benzoates - adverse effects | Hydrazines - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Thrombopoietin - therapeutic use | Receptors, Fc - therapeutic use | Carrier Proteins - adverse effects | Thrombocytopenia - drug therapy | Thrombopoietin - adverse effects | Carrier Proteins - therapeutic use | Thrombopoietin - physiology | Hydrazines - adverse effects | Pyrazoles - adverse effects | Thrombocytopenia | Care and treatment | Research | Biomimetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies
by Maan, Raoel and De Knegt, Robert J and Veldt, Bart J
Drugs, ISSN 0012-6667, 11/2015, Volume 75, Issue 17, pp. 1981 - 1992
Thrombocytopenia (platelet count <150 x 10(9)/L) often complicates chronic liver disease, impeding optimal management of these patients. The prevalence of this... 
SUSTAINED VIROLOGICAL RESPONSE | HEPATOCELLULAR-CARCINOMA | ANTIVIRAL THERAPY | AKR-501 YM477 | CHRONIC HEPATITIS-C | PLATELET COUNT | PEGYLATED-INTERFERON | HUMAN THROMBOPOIETIN | ADVANCED FIBROSIS | PHARMACOLOGY & PHARMACY | TOXICOLOGY | HCV INFECTION | Thiophenes - therapeutic use | Hydrazines - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Thrombopoietin - therapeutic use | Hepatitis C, Chronic - complications | Thiazoles - therapeutic use | Thrombocytopenia - complications | Receptors, Fc - therapeutic use | Receptors, Thrombopoietin - agonists | Thrombocytopenia - drug therapy | Liver Diseases - complications | Disease Management | Chronic Disease
Journal Article
Details down arrow
6. Full Text Thrombopoietic Agents for the Treatment of Persistent and Chronic Immune Thrombocytopenia in Children
by Ramaswamy, Kavitha, MD and Hsieh, Loan, MD and Leven, Emily, BA and Thompson, Michaela V., BA and Nugent, Diane, MD and Bussel, James B., MD
Journal of Pediatrics, The, ISSN 0022-3476, 2014, Volume 165, Issue 3, pp. 600 - 605.e4
Objectives To determine the safety, tolerability, or efficacy of 2 licensed thrombopoietic agents in children with persistent and chronic immune... 
Pediatrics | EFFICACY | SAFETY | ROMIPLOSTIM | PURPURA | DOUBLE-BLIND | ELTROMBOPAG | PEDIATRICS | LONG-TERM TREATMENT | Hydrazines - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Child, Preschool | Male | Thrombopoietin - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Receptors, Fc - therapeutic use | Young Adult | Adolescent | Female | Retrospective Studies | Child | Chronic Disease | Thrombocytopenia | Drug therapy | Medical colleges
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study
by Neunert, Cindy and Despotovic, Jenny and Haley, Kristina and Lambert, Michele P and Nottage, Kerri and Shimano, Kristin and Bennett, Carolyn and Klaassen, Robert and Stine, Kimo and Thompson, Alexis and Pastore, Yves and Brown, Travis and Forbes, Peter W and Grace, Rachael F and Pediat ITP Consortium North Amer and Pediatric ITP Consortium of North America (ICON)
Pediatric Blood & Cancer, ISSN 1545-5009, 08/2016, Volume 63, Issue 8, pp. 1407 - 1413
Background Data on second‐line treatment options for pediatric patients with immune thrombocytopenia (ITP) are limited. Thrombopoietin receptor agonists... 
treatment | ICON | thrombopoietin receptor agonists | immune thrombocytopenia | pediatrics | PURPURA ITP | CHRONIC IMMUNE THROMBOCYTOPENIA | EFFICACY | ROMIPLOSTIM | OPEN-LABEL | ONCOLOGY | DOUBLE-BLIND | ELTROMBOPAG | PLACEBO-CONTROLLED TRIAL | JAPANESE PATIENTS | HEMATOLOGY | LONG-TERM TREATMENT | Benzoates - adverse effects | Hydrazines - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Male | Thrombopoietin - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - blood | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Receptors, Fc - therapeutic use | Receptors, Thrombopoietin - agonists | Platelet Count | Thrombopoietin - adverse effects | Adolescent | Female | Retrospective Studies | Child | Hydrazines - adverse effects | Pyrazoles - adverse effects | Pediatrics | Health aspects | Children | Consortia | Treatment | Thrombopoietin Receptor Agonists | Immune Thrombocytopenia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia
by Olnes, Matthew J and Scheinberg, Phillip and Calvo, Katherine R and Desmond, Ronan and Tang, Yong and Dumitriu, Bogdan and Parikh, Ankur R and Soto, Susan and Biancotto, Angelique and Feng, Xingmin and Lozier, Jay and Wu, Colin O and Young, Neal S and Dunbar, Cynthia E
The New England Journal of Medicine, ISSN 0028-4793, 07/2012, Volume 367, Issue 1, pp. 11 - 19
A phase 2 study showed a 44% response rate with eltrombopag, an oral thrombopoietin mimetic, among 25 patients with refractory aplastic anemia. Severe aplastic... 
STIMULATING FACTOR | SURVIVAL | MEDICINE, GENERAL & INTERNAL | IMMUNOSUPPRESSIVE THERAPY | STEM-CELLS | BONE-MARROW | C-MPL | RABBIT ANTITHYMOCYTE GLOBULIN | MARROW-TRANSPLANTATION | THROMBOPOIETIN | MICE LACKING | Benzoates - adverse effects | Recurrence | Hydrazines - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Bone Marrow Cells - cytology | Humans | Middle Aged | Male | Benzoates - administration & dosage | Young Adult | Pyrazoles - administration & dosage | Adolescent | Anemia, Aplastic - drug therapy | Adult | Female | Aged | Chronic Disease | Hydrazines - administration & dosage | Drug Resistance | Anemia, Aplastic - pathology | Hydrazines - adverse effects | Pyrazoles - adverse effects | Eltrombopag | Hematopoiesis | Patient outcomes | Aplastic anemia | Causes of | Dosage and administration | Research | Drug therapy | Hypoplasia | Immune response | Transplants & implants | Anemia | Transplantation | Patients | Progenitor cells | Hematopoietic stem cells | Blood | Immunosuppressive agents | Thrombopoietin | Hemopoiesis | Immunosuppression | Pancytopenia | Fibrosis | Stem cells | Hemoglobin | Bone marrow | Platelets | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text TPO receptor agonist for chronic idiopathic thrombocytopenic purpura
by Zeng, Yan and Duan, Xin and Xu, Jiajun and Ni, Xun
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2011, Issue 7, p. CD008235
Background Chronic idiopathic thrombocytopenic purpura (ITP) is an acquired autoimmune disorder that is characterized predominantly by a low platelet count.... 
ADULT PATIENTS | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | EFFICACY | SAFETY | ROMIPLOSTIM | AMG-531 | GUIDELINES | DOUBLE-BLIND | ELTROMBOPAG | SPLENECTOMY | Benzoates - adverse effects | Hydrazines - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Thrombopoietin - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Randomized Controlled Trials as Topic | Receptors, Fc - therapeutic use | Receptors, Thrombopoietin - agonists | Thrombopoietin - adverse effects | Chronic Disease | Hydrazines - adverse effects | Pyrazoles - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
by Bussel, James B, MD and Provan, Drew, MD and Shamsi, Tahir, MD and Cheng, Gregory, MD and Psaila, Bethan, MD and Kovaleva, Lidia, MD and Salama, Abdulgabar, MD and Jenkins, Julian M, MSc and Roychowdhury, Debasish, MD and Mayer, Bhabita, MSc and Stone, Nicole, PhD and Arning, Michael, MD
Lancet, The, ISSN 0140-6736, 2009, Volume 373, Issue 9664, pp. 641 - 648
Summary Background Eltrombopag is an oral, non-peptide, thrombopoietin-receptor agonist that stimulates thrombopoiesis, leading to increased platelet... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | IN-VITRO | EFFICACY | ITP | SAFETY | AMG-531 | GROWTH | ADULTS | QUALITY-OF-LIFE | RECEPTOR AGONIST | TPOR AGONIST | Benzoates - adverse effects | Hydrazines - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - complications | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Humans | Middle Aged | Male | Hemorrhage - prevention & control | Purpura, Thrombocytopenic, Idiopathic - blood | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Young Adult | Platelet Count | Hemorrhage - etiology | Aged, 80 and over | Adult | Female | Aged | Chronic Disease | Hydrazines - adverse effects | Pyrazoles - adverse effects | Thrombocytopenic purpura | Dosage and administration | Eltrombopag | Drug therapy | Heart failure | Drugs | Heart attacks | Blood platelets | Clinical trials | Monoclonal antibodies | Data collection | Placebo effect | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Thrombopoietin-Receptor Agonists for Primary Immune Thrombocytopenia
by Imbach, Paul and Crowther, Mark
The New England Journal of Medicine, ISSN 0028-4793, 08/2011, Volume 365, Issue 8, pp. 734 - 741
A young woman with immune thrombocytopenia (ITP) who has been treated with a thrombopoietin-receptor agonist presents for advice regarding long-term treatment.... 
AUTOANTIBODIES | ADULT PATIENTS | MEDICINE, GENERAL & INTERNAL | PLATELET COUNTS | EFFICACY | ITP | SAFETY | PURPURA | ROMIPLOSTIM | DOUBLE-BLIND | ELTROMBOPAG | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Recombinant Fusion Proteins - pharmacology | Benzoates - chemistry | Humans | Recombinant Fusion Proteins - therapeutic use | Thrombopoietin - therapeutic use | Receptors, Fc - therapeutic use | Hydrazines - chemistry | Pyrazoles - chemistry | Thrombocytopenia - drug therapy | Adult | Female | Thrombopoietin - chemistry | Autoimmune Diseases - drug therapy | Pyrazoles - pharmacology | Receptors, Fc - chemistry | Hydrazines - pharmacology | Hydrazines - therapeutic use | Thrombocytopenia - immunology | Thrombopoietin - pharmacology | Recombinant Fusion Proteins - chemistry | Receptors, Thrombopoietin - agonists | Platelet Count | Benzoates - pharmacology | Practice Guidelines as Topic | Thrombocytopenia | Case studies | Causes of | Care and treatment | Diagnosis | Menstruation | Hematology | Bone marrow | Adults | Patients | Thrombopoietin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia
by Afdhal, Nezam H and Giannini, Edoardo G and Tayyab, Ghias and Mohsin, Aftab and Lee, Jin-Woo and Andriulli, Angelo and Jeffers, Lennox and McHutchison, John and Chen, Pei-Jer and Han, Kwang-Hyub and Campbell, Fiona and Hyde, Denise and Brainsky, Andres and Theodore, Dickens and ELEVATE Study Grp and ELEVATE Study Group
The New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 8, pp. 716 - 724
In this trial involving patients with cirrhosis and thrombocytopenia, treatment with eltrombopag before invasive procedures reduced the need for platelet... 
MEDICINE, GENERAL & INTERNAL | COAGULATION | ARTICLE | PORTAL-VEIN THROMBOSIS | CHRONIC LIVER-DISEASE | Benzoates - adverse effects | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Humans | Middle Aged | Male | Hemorrhage - prevention & control | Thrombocytopenia - complications | Platelet Transfusion - statistics & numerical data | Young Adult | Aged, 80 and over | Adult | Female | Pyrazoles - adverse effects | Hydrazines - therapeutic use | Double-Blind Method | Hemorrhage - epidemiology | Liver Cirrhosis - complications | Receptors, Thrombopoietin - agonists | Receptors, Thrombopoietin - genetics | Platelet Count | Adolescent | Aged | Chronic Disease | Elective Surgical Procedures | Hydrazines - adverse effects | Thrombocytopenia | Treatment outcome | Usage | Care and treatment | Eltrombopag | Causes of | Venous thrombosis | Health aspects | Liver cirrhosis | Cirrhosis | Medical research | Liver diseases | Platelets | Thrombosis | Bleeding | Thrombopoietin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
by Kuter, David J and Bussel, James B and Newland, Adrian and Baker, Ross I and Lyons, Roger M and Wasser, Jeffrey and Viallard, Jean‐Francois and Macik, Gail and Rummel, Mathias and Nie, Kun and Jun, Susie
British Journal of Haematology, ISSN 0007-1048, 05/2013, Volume 161, Issue 3, pp. 411 - 423
Summary Romiplostim was effective, safe, and well‐tolerated over 6–12 months of continuous treatment in Phase 3 trials in patients with immune thrombocytopenia... 
autoimmunity | thrombopoietic agents | thrombopoiesis | platelets | TPO receptor agonists | Autoimmunity | Thrombopoiesis | Platelets | Thrombopoietic agents | PURPURA ITP | AUTOANTIBODIES | MANAGEMENT | AMG-531 | DOUBLE-BLIND | ELTROMBOPAG | HEMATOLOGY | STANDARD | Myocardial Infarction - chemically induced | Purpura, Thrombocytopenic, Idiopathic - complications | Thrombosis - chemically induced | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Thrombopoietin - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Receptors, Fc - therapeutic use | Dose-Response Relationship, Drug | Splenectomy | Self Administration | Hemorrhage - etiology | Injections, Subcutaneous | Adult | Female | Purpura, Thrombocytopenic, Idiopathic - surgery | Bone Marrow Diseases - chemically induced | Combined Modality Therapy | Thrombocytopenia - chemically induced | Platelet Count | Thrombopoietin - adverse effects | Aged | Thrombocytopenia | Complications and side effects | Care and treatment
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14.